Lumena Pharmaceuticals, a clinical-stage biotech developing candidates for rare liver diseases, filed on Wednesday with the SEC to raise up to $75 million in an initial public offering. The San Diego, CA-based company, which was founded in 2011, plans to list on the NASDAQ under the symbol LIVR. Lumena Pharmaceuticals initially filed confidentially on February 28, 2014. Citi, Cowen & Company and Leerink Partners are the joint bookrunners on the deal. No pricing terms were disclosed.
